Tus-Pharmaceutical Group: Announcement regarding the pledge of a portion of the equity of one of the controlling shareholders by the concerted action person.
Tus-Pharmaceutical Group: Announcement Regarding Appointment of Secretary of the Board of Directors
Tus-Pharmaceutical Group: Announcement regarding the resignation of the company's vice president and board of directors secretary.
Tus-Pharmaceutical Group: Legal opinion on the 2023 shareholder meeting of Tus-Pharmaceutical Group Co., Ltd.
Tus-Pharmaceutical Group: Announcement of resolutions of the 2023 Shareholders' Meeting (2024-027)
Tus-Pharmaceutical Group: Announcement on amending the Company's Articles of Association.
Tus-Pharmaceutical Group: Notice on holding the shareholder meeting for the year 2023.
Tus-Pharmaceutical Group: Internal Audit Management Standards
Tus-Pharmaceutical Group: Materials for the 2023 Shareholders' Meeting.
Enlightenment Pharmaceutical: Announcement on the pledge of some of the shares of the controlling shareholders\' concerted actions
Enlighten Pharmaceutical: Report on the Audit Committee of the Board of Directors on the performance of supervisory duties by accounting firms in 2023
Enlighten Pharmaceutical: Sensitive Information Investigation System (revised in March 2024)
Enlighten Pharmaceutical: Announcement on the Company's Accumulation of Goodwill Impairment Preparation
Enlighten the Pharmaceutical Industry: Internal Control Self-Assessment Report
Enlightenment Pharmaceuticals: 2023 Annual Financial Report
Enlightenment Pharmaceutical: 2024-008 Announcement on Responding to the Shenzhen Stock Exchange Inquiry Letter
Enlightenment Pharmaceutical: Legal Opinion of Enlightenment Pharmaceutical\'s 2024 First Extraordinary General Meeting of Shareholders
Enlightenment Pharmaceutical: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Enlighten Pharmaceutical: 2024 First Extraordinary General Meeting of Shareholders Meeting Information
Enlightenment Pharmaceutical: Announcement on Wholly-owned Subsidiaries Investing in the Construction of Industrial Tourist Attractions
No Data